Results 301 to 310 of about 152,178 (350)

Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer.

New England Journal of Medicine
BACKGROUND Outcomes in patients with hormone receptor-positive metastatic breast cancer worsen after one or more lines of endocrine-based therapy. Trastuzumab deruxtecan has shown efficacy in patients with metastatic breast cancer with low expression of ...
A. Bardia, Xichun Hu, R. Dent, K. Yonemori, C. Barrios, J. O’Shaughnessy, H. Wildiers, J. Pierga, Qingyuan Zhang, C. Saura, L. Biganzoli, J. Sohn, Seock-Ah Im, C. Lévy, William Jacot, N. Begbie, J. Ke, Gargi Patel, G. Curigliano   +18 more
semanticscholar   +1 more source

Randomized, Phase II Study of Trastuzumab Beyond Progression in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: WJOG7112G (T-ACT Study).

Journal of Clinical Oncology, 2020
PURPOSE This study evaluated the continuous use of trastuzumab beyond progression (TBP) in human epidermal growth factor receptor 2 (HER2)-positive advanced gastric or gastroesophageal junction (G/GEJ) cancer.
A. Makiyama, Y. Sukawa, T. Kashiwada, J. Kawada, A. Hosokawa, Y. Horie, A. Tsuji, T. Moriwaki, H. Tanioka, K. Shinozaki, K. Uchino, H. Yasui, H. Tsukuda, K. Nishikawa, Hiroyasu Ishida, T. Yamanaka, K. Yamazaki, S. Hironaka, T. Esaki, N. Boku, I. Hyodo, K. Muro   +21 more
semanticscholar   +1 more source

Trastuzumab

Reactions Weekly, 2019
  +9 more sources

Trastuzumab

Reactions Weekly, 2009
Edith A, Perez, Frances M, Palmieri, Shelly M, Brock   +2 more
openaire   +3 more sources

Trastuzumab/trastuzumab emtansine

Reactions Weekly, 2023
openaire   +1 more source

Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies

Ca-A Cancer Journal for Clinicians, 2022
Paolo Tarantino, Roberto Carmagnani Pestana, Shanu Modi   +2 more
exaly  

Anastrozole/trastuzumab/trastuzumab emtansine

Reactions Weekly, 2022
openaire   +1 more source

Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial

Nature Medicine, 2023
Fernanda Mosele, Elise Deluche
exaly  

Pertuzumab/trastuzumab/trastuzumab emtansine

Reactions Weekly, 2021
openaire   +1 more source

Trastuzumab-emtansine/trastuzumab

Reactions Weekly, 2020
openaire   +1 more source